Evidence map›Paper›PMID 26974432›Full record

Trial reportPloS one2016

Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants.

Roma Chilengi, Michelo Simuyandi, Lauren Beach, Katayi Mwila, Sylvia Becker-Dreps, Devy M Emperador, Daniel E Velasquez, Samuel Bosomprah, Baoming Jiang

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03602053 (An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03602053 phase2 / phase3completednot on this mapstarted 2019, after this paper: background citation

An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants

TypeinterventionalSponsorCentre for Infectious Disease Research in ZambiaRan2019 to 2019Enrolled450ConditionsDiarrhea, Diarrhea RotavirusArmsROTAVAC®, ROTAVAC 5D, Rotarix®
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Review
  12. Article
  13. Breast Milk-Derived Antibodies Impair Vaccine Immunity in Suckling Mice.Journal of immunology (Baltimore, Md. : 1950) · 2024
    Article
  14. Impact of dosing schedules on performance of rotavirus vaccines in Ghana.medRxiv : the preprint server for health sciences · 2024
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Roma ChilengiCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Michelo SimuyandiCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Lauren BeachCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Katayi MwilaCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Sylvia Becker-DrepsUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Devy M EmperadorCentres for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Daniel E VelasquezCentres for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Samuel BosomprahCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Baoming JiangCentres for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Centre for Infectious Disease Research in Zambia · ZMUniversity of North Carolina at Chapel Hill · US

Funding

Causes of rotavirus vaccine failure in Zambian childrenR01AI099601 · NIAID · CENTRE FOR INFECTIOUS DISEASE RESEARCH · PI CHILENGI, ROMA · 2012 to 2016
$643k
NIAID NIH HHS R01 AI099601
6 · The paper itself

Abstract

introductionLive attenuated oral vaccines against rotavirus (RV) have been shown to be less efficacious in children from developing countries. Reasons for this disparity are not fully understood. We assessed the role of maternal factors including breast milk RV-specific IgA, transplacentally acquired infant serum RV-specific IgG and maternal HIV status in seroconversion among Zambian infants routinely immunized with Rotarix™ (RV1).

methods420 mother-child pairs were recruited at infant age 6-12 weeks in Lusaka. Clinical information and samples were collected at baseline and at one month following the second dose of RV1. Determination of breast milk RV-specific IgA and serum RV-specific IgA and IgG was done using standardized ELISA. Seroconversion was defined as a ≥ 4 fold rise in serum IgA titre from baseline to one-month post RV1 dose 2, while seropositivity of IgA was defined as serum titre ≥ 40 and antibody variables were modelled on log-base 2. Logistic regression was used to identify predictors of the odds of seroconversion.

resultsBaseline infant seropositivity was 25.5% (91/357). The seroconversion frequency was 60.2% (130/216). Infants who were IgA seropositive at baseline were less likely to seroconvert compared to their seronegative counterparts (P = 0.04). There was no evidence of an association between maternal HIV status and seroconversion (P = 0.25). Higher titres of breast milk rotavirus-specific IgA were associated with a lower frequency of seroconverson (Nonparametric test for trend Z = -2.84; P<0.01): a two-fold increase in breast milk RV-specific IgA titres was associated with a 22% lower odds of seroconversion (OR = 0.80; 95% CI = 0.68-0.94; P = 0.01). There was seasonal variation in baseline breast milk rotavirus-specific IgA titres, with significantly higher GMTs during the cold dry months (P = 0.01).

conclusionLow immunogenicity of RV1 vaccine could be explained in part by exposure to high antibody titres in breast milk and early exposure to wild-type rotavirus infections. Potential interference of anti-RV specific IgA in breast milk and pre-vaccination serum RV specific-IgA and IgG titres with RV1 seroconversion and effectiveness requires further research.

Indexed as

Breast FeedingAntibodies, ViralFemaleHumansImmunoglobulin AImmunoglobulin GInfantInfant, NewbornMaleRotavirus InfectionsRotavirus VaccinesVaccines, AttenuatedZambiaAntibodies, ViralImmunoglobulin AImmunoglobulin GRIX4414 vaccineRotavirus VaccinesVaccines, Attenuated

Identifiers

PMID26974432
PMCPMC4790930
OpenAlexW2299269284

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.